Global In-Vitro Colorectal Cancer Screening Tests Market Size, Share, Forecast Report, 2024-2033
The global in-vitro colorectal cancer screening tests market size was exhibited at USD 864.58 million in 2023 and is projected to hit around USD 1,167.58 million by 2033, growing at a CAGR of 3.05% during the forecast period of 2024 to 2033.
Key Takeaways:
In-Vitro Colorectal Cancer Screening Tests Market Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 864.58 Million |
| Market Size by 2033 | USD 1,167.58 Million |
| Growth Rate From 2024 to 2033 | CAGR of 3.05% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Test Type, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Abbott, Beckman Coulter, Inc., Epigenomics, Eiken Chemical Co., Ltd., Sysmex Corporation, Siemens Healthcare GmbH, Quest Diagnostics Incorporated, OncocyteCorporation, Merck KGaA, ImmunosticsInc., Kyowa Kirin Co., Ltd., Randox Laboratories Ltd. and R-Biopharm AG |
The growing prevalence of colon and rectal melanoma cases and increasing demand for effective genetic testing are the prime factors boosting the market. According to data published by the American Cancer Society in March 2023, colorectal cancer ranks as the third most common cause of cancer-related deaths in the United States. The report estimates that approximately 153,020 individuals will receive a diagnosis of colorectal cancer in the same year, with 52,550 deaths attributed to the disease. These statistics highlight the significant impact of colorectal malignancy on the population and the need for effective prevention, early detection, and treatment measures to reduce its burden.
The increasing prevalence of colorectal cancer is a significant driver for market growth. A study published in the Chinese Medical Journal in March 2023 highlighted the rising incidence of cancer in China, with approximately 4,820,000 new cases reported in 2023. Among these cases, there were 592,232 individuals diagnosed with colorectal cancer. This higher incidence has resulted in an increased demand for screening tests and treatments for tumors.
Further, according to a study published by MDPI in April 2023, colorectal cancer is recognized as one of the most prevalent in Canada, with an estimated 24,800 cases diagnosed in 2021. While colorectal cancer cases in adults under the age of 50 account for approximately 8% of all cases in Canada, recent research has revealed a significant increase in the incidence of colon malignancy among younger individuals. This upward trend in the prevalence of colon cancer, particularly among the younger population, is projected to have a positive impact on market growth. The need for effective screening and treatment options is expected to rise in order to address this emerging public health concern.
Furthermore, early and accurate detection of colon disease through in-vitro screening tests is crucial in reducing the burden of the disease and improving mortality rates. Regular screening enables the early identification of CRC, which has been associated with a potential 60% reduction in CRC-related deaths. The utilization of in-vitro screening tests is expected to contribute to an improvement in an average 5-year survival rate from 46% to 73% when regular periodic screening is conducted annually. These screening tests play a significant role in the early detection and management of CRC, ultimately leading to better patient outcomes and increased survival rates.
The market experienced a significant impact from the COVID-19 pandemic, leading to a decline in screenings during the initial phase of the pandemic. According to an article published by MDPI in May 2023, a study in the Canada revealed a decline in the amount of colorectal cancer diagnoses throughout the COVID-19 pandemic compared to the pre-pandemic period. However, as the pandemic situation has improved and healthcare services have resumed normal operations, colorectal malignance screening procedures are gradually returning to normal, resulting in the market regaining its momentum. As a result, the market is expected to exhibit regular growth during the forecast period, as screening activities continue to be conducted as per standard protocols.
Moreover, the market is driven by the increasing focus of federal regulatory bodies on the effectiveness of biomarker tests. Key companies are incorporating highly informative biomarkers, such as protein biomarkers, KRAS gene, and DNA methylation biomarkers (NDRG4 and BMP3), to ensure high sensitivity in the identification of colorectal cancer (CRC). Similarly, rising initiatives aimed at creating awareness about the diagnosis of colon and rectal tumour, which contribute to revenue generation. Two charitable organizations of UK, Bowel Cancer UK and the Beating Bowel Cancer every year host an annual event in the month of April to educate the public, raise the awareness about bowel disorders, and funds for treating this medical condition.
Segments Insights:
Test Type Insights
Based on test type, fecal occult blood tests dominated the market with a revenue share of 83.0% in 2023. The presence of blood in the stool can indicate various conditions, including colorectal cancer, polyps, ulcers, or hemorrhoids. The fecal occult blood test is a commonly preferred screening test due to its high effectiveness in detecting bowel malignance. Factors such as the increasing prevalence of colorectal cancer and the growing utilization of fecal occult blood test are anticipated to drive the growth of this segment.
The segment growth is further driven by the advancements made by market players, which have led to increased usage of their products. For instance, in June 2023, W.H.P.M., Inc obtained 510(k) marketing approval from the U.S. FDA for their Hemosure Accu-Reader A100, Fecal Occult Blood Test. These developments, coupled with the rising prevalence of colorectal cancer, are anticipated to contribute to the growth of the market.
The biomarker tests segment is expected to experience fastest growth rate throughout the projection period. The use of Tumor M2-PK stool tests is gaining traction in the biomarker testing field and is projected to hold a significant market share. These tests offer increased accuracy and sensitivity by analyzing the presence of biomarkers for colorectal disease diagnosis. On the other hand, methylated gene testing provides information on pre-malignant colorectal neoplasia and is expected to exhibit the fastest CAGR during the forecast period.
Regional Insights
North America region dominated the market with a share of over 44.0% in 2023. The growth of the region is expected to be fueled by the rising prevalence of colon malignancy, advancements in technology, and increasing initiatives focused on malignancy prevention.The United States is projected to hold a significant share in the market in North America due to its advanced healthcare infrastructure for screening and the increasing burden of colorectal malignancy.
According to data published by the American Cancer Society in 2023, it is estimated that there will be 153,020 new cases of colon and rectum malignances in the U.S. Among these cases, 106,970 are expected to be colon tumors, while 46,050 are expected to be rectum malignancies. Additionally, data from the same source indicates that 151,030 colon and rectum malignance cases were detected in 2023, and 149,500 cases were detected in 2021. These statistics highlight the high prevalence of colon and rectum cancers in the country, which is expected to drive the growth of the market.
Asia Pacific is anticipated to experience the highest growth rate during the projection period, primarily driven by developing economies such as China and India. These countries possess significant growth potential due to their large customer base. The region is witnessing a growing concern for colorectal malignancy, particularly among the rising geriatric population and due to changes in lifestyle in Asian countries. This increasing prevalence of colorectal cancer in Asia Pacific is expected to drive the demand for in-vitro screening, contributing to the market's growth in the region.
Some of the prominent players in the In-vitro colorectal cancer screening tests market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global in-vitro colorectal cancer screening tests market.
Test Type
By Region
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Test type segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Test Type Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing incidence of colon and rectal cancers
3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
3.2.2. Market Restraint Analysis
3.2.2.1. Pending investigational evidence for certain genetic screening tests
3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Test Type Business Analysis
4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
4.2. Fecal Occult Blood Tests
4.2.1. Fecal Occult Blood Tests Market, 2021 - 2033
4.2.2. Guaiac FOB Stool Test
4.2.2.1. Guaiac FOB Stool Test Market, 2021 - 2033
4.2.3. Immuno-FOB Agglutination Test
4.2.3.1. Immuno-FOB Agglutination Test Market, 2021 - 2033
4.2.4. Lateral Flow Immuno-FOB Test
4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2021 - 2033
4.2.5. Immuno-FOB ELISA Test
4.2.5.1. Immuno-FOB ELISA Test Market, 2021 - 2033
4.3. Biomarker Tests Market
4.3.1. Biomarker Tests Market, 2021 - 2033
4.3.2. Tumor M2-PK Stool Test
4.3.2.1. Tumor M2-PK Stool Test Market, 2021 - 2033
4.3.3. Transferrin Assays
4.3.3.1. Transferrin Assays Market, 2021 - 2033
4.3.4. Immuno-FOB ELISA Test
4.3.4.1. Immuno-FOB ELISA Test Market, 2021 - 2033
4.4. CRC DNA Screening Tests
4.4.1. CRC DNA Screening Tests Market, 2021 - 2033
4.4.2. Methylated Gene Testing
4.4.2.1. Methylated Gene Testing Market, 2021 - 2033
4.4.3. Panel DNA Tests
4.4.3.1. Panel DNA Tests Market, 2021 - 2033
Chapter 5. Regional Business Analysis
5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
5.2. North America
5.2.1. SWOT Analysis
5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.2.3. U.S.
5.2.3.1. Key Country Dynamics
5.2.3.2. Target Disease Prevalence
5.2.3.3. Competitive Scenario
5.2.3.4. Regulatory Framework
5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.2.4. Canada
5.2.4.1. Key Country Dynamics
5.2.4.2. Target Disease Prevalence
5.2.4.3. Competitive Scenario
5.2.4.4. Regulatory Framework
5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3. Europe
5.3.1. SWOT Analysis
5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.3. UK
5.3.3.1. Key Country Dynamics
5.3.3.2. Target Disease Prevalence
5.3.3.3. Competitive Scenario
5.3.3.4. Regulatory Framework
5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.4. Germany
5.3.4.1. Key Country Dynamics
5.3.4.2. Target Disease Prevalence
5.3.4.3. Competitive Scenario
5.3.4.4. Regulatory Framework
5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.5. France
5.3.5.1. Key Country Dynamics
5.3.5.2. Target Disease Prevalence
5.3.5.3. Competitive Scenario
5.3.5.4. Regulatory Framework
5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.6. Italy
5.3.6.1. Key Country Dynamics
5.3.6.2. Target Disease Prevalence
5.3.6.3. Competitive Scenario
5.3.6.4. Regulatory Framework
5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.7. Spain
5.3.7.1. Key Country Dynamics
5.3.7.2. Target Disease Prevalence
5.3.7.3. Competitive Scenario
5.3.7.4. Regulatory Framework
5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.8. Sweden
5.3.8.1. Key Country Dynamics
5.3.8.2. Target Disease Prevalence
5.3.8.3. Competitive Scenario
5.3.8.4. Regulatory Framework
5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.9. Norway
5.3.9.1. Key Country Dynamics
5.3.9.2. Target Disease Prevalence
5.3.9.3. Competitive Scenario
5.3.9.4. Regulatory Framework
5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.10. Denmark
5.3.10.1. Key Country Dynamics
5.3.10.2. Target Disease Prevalence
5.3.10.3. Competitive Scenario
5.3.10.4. Regulatory Framework
5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.11. Russia
5.3.11.1. Key Country Dynamics
5.3.11.2. Target Disease Prevalence
5.3.11.3. Competitive Scenario
5.3.11.4. Regulatory Framework
5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.3.12. Netherlands
5.3.12.1. Key Country Dynamics
5.3.12.2. Target Disease Prevalence
5.3.12.3. Competitive Scenario
5.3.12.4. Regulatory Framework
5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4. Asia Pacific
5.4.1. SWOT Analysis
5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.3. Japan
5.4.3.1. Key Country Dynamics
5.4.3.2. Target Disease Prevalence
5.4.3.3. Competitive Scenario
5.4.3.4. Regulatory Framework
5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.4. China
5.4.4.1. Key Country Dynamics
5.4.4.2. Target Disease Prevalence
5.4.4.3. Competitive Scenario
5.4.4.4. Regulatory Framework
5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.5. India
5.4.5.1. Key Country Dynamics
5.4.5.2. Target Disease Prevalence
5.4.5.3. Competitive Scenario
5.4.5.4. Regulatory Framework
5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.6. Australia
5.4.6.1. Key Country Dynamics
5.4.6.2. Target Disease Prevalence
5.4.6.3. Competitive Scenario
5.4.6.4. Regulatory Framework
5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.7. Thailand
5.4.7.1. Key Country Dynamics
5.4.7.2. Target Disease Prevalence
5.4.7.3. Competitive Scenario
5.4.7.4. Regulatory Framework
5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.4.8. South Korea
5.4.8.1. Key Country Dynamics
5.4.8.2. Target Disease Prevalence
5.4.8.3. Competitive Scenario
5.4.8.4. Regulatory Framework
5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.5. Latin America
5.5.1. SWOT Analysis
5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.5.3. Brazil
5.5.3.1. Key Country Dynamics
5.5.3.2. Target Disease Prevalence
5.5.3.3. Competitive Scenario
5.5.3.4. Regulatory Framework
5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.5.4. Mexico
5.5.4.1. Key Country Dynamics
5.5.4.2. Target Disease Prevalence
5.5.4.3. Competitive Scenario
5.5.4.4. Regulatory Framework
5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.5.5. Argentina
5.5.5.1. Key Country Dynamics
5.5.5.2. Target Disease Prevalence
5.5.5.3. Competitive Scenario
5.5.5.4. Regulatory Framework
5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.6. MEA
5.6.1. SWOT Analysis
5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.6.3. South Africa
5.6.3.1. Key Country Dynamics
5.6.3.2. Target Disease Prevalence
5.6.3.3. Competitive Scenario
5.6.3.4. Regulatory Framework
5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.6.4. Saudi Arabia
5.6.4.1. Key Country Dynamics
5.6.4.2. Target Disease Prevalence
5.6.4.3. Competitive Scenario
5.6.4.4. Regulatory Framework
5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.6.5. UAE
5.6.5.1. Key Country Dynamics
5.6.5.2. Target Disease Prevalence
5.6.5.3. Competitive Scenario
5.6.5.4. Regulatory Framework
5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
5.6.6. Kuwait
5.6.6.1. Key Country Dynamics
5.6.6.2. Target Disease Prevalence
5.6.6.3. Competitive Scenario
5.6.6.4. Regulatory Framework
5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2021 - 2033
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market Share Analysis, 2022
6.4. Company Profiles/Listing
6.4.1. Abbott
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. Beckman Coulter Inc
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Eiken Chemical Co., Ltd.
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Epigenomics
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Sysmex Corporation
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Siemens Healthcare GmbH
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Quest Diagnostics Incorporated
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. OncoCyte Corporation
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Merck KGaA
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. Immunostics Inc.
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. Kyowa Kirin Co. Ltd.
6.4.11.1. Overview
6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.11.3. Product Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. Randox Laboratories Ltd.
6.4.12.1. Overview
6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.12.3. Product Benchmarking
6.4.12.4. Strategic Initiatives
6.4.13. R-Biopharm AG
6.4.13.1. Overview
6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.13.3. Product Benchmarking
6.4.13.4. Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers